First human test of VIS649 drug for kidney disease shows safety
NCT ID NCT03719443
First seen May 14, 2026 · Last updated May 16, 2026 · Updated 1 time
Summary
This early-stage study tested a new drug called VIS649 in 51 healthy adults to see if it is safe and how the body processes it. VIS649 is designed to target a protein linked to IgA nephropathy, a kidney disease. The study compared different single doses of the drug against a placebo. The main goal was to check for side effects and measure drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN A NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
California Clinical Trials Medical Group
Glendale, California, 91206, United States
Conditions
Explore the condition pages connected to this study.